COVID-19 Vaccines Have Arrived In Nigeria!
Nigeria received nearly 4 million doses of the COVID-19 vaccine, shipped via the COVAX Facility, a partnership between CEPI, Gavi, UNICEF and WHO.
The delivery is part of a first wave of arrivals in Nigeria that will continue in the coming days and weeks. The arrival marked a historic step towards the goal to ensure equitable distribution of COVID-19 vaccines globally, in what will be the largest vaccine procurement and supply operation in history.
TRENDING NOW
- AfDB signs $400k grant with SEC to strengthen securities market regulation
- NYSC Batch A: Date for Stream II confirmed, Error Printing Green Card Resolved
- CBN Covid-19 Loan for Business Owners Reopened – Click here to Apply
- Nigerian Army College of Nursing Post-Basic Midwifery Admission Form for 2021/2022 Academic Session
- Apply for Supervisor – Laundry at Marriott International
From Mumbai to Abuja, COVAX shipped 3.94 million doses of the AstraZeneca/Oxford vaccine, manufactured by the Serum Institute of India (SII).
“The UN Country Team in Nigeria reiterates its commitment to support the vaccination campaign in Nigeria and help contain the spread of the virus,” said Edward Kallon, UN Resident Coordinator in Nigeria. “The arrival of these vaccines in Abuja today marks a milestone for the COVAX Facility in its unprecedented effort to deliver at least 2 billion doses of COVID-19 vaccines globally by the end of 2021.”
The arrival of the CIVID-19 vaccine will enable the National Primary Health Care Development Agency (NPHCDA) to commence the vaccination of Nigerians in priority groups, starting with frontline healthcare workers.
Dr Walter Kazadi Mulombo, WHO Representative in Nigeria, said: “It is heart-warming to witness this epoch-making event and WHO wishes to congratulate the government of Nigeria for its participation in the global vaccine collaboration (COVAX) efforts and its commitment to protecting Nigerians against this pandemic.
According to him, “Vaccines are a critical new tool in the battle against COVID-19; therefore, this is a step in the right direction. These vaccines have undergone rigorous regulatory processes at global and country level and have been deemed safe and effective.”
COVAX has built a diverse portfolio of vaccines suitable for a range of settings and populations, and is on track to meet its goal of delivering at least 2 billion doses of vaccine to participating countries around the globe in 2021, including at least 1.3 billion donor-funded doses to the 92 lower-income COVAX Facility participants supported by the Gavi COVAX AMC.
